PROTOCOLOS CLÍNICOS E DIRETRIZES TERAPÊUTICAS

Protocolos Clínicos e Diretrizes Terapêuticas with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995;86(2):457-62. 83. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995;332(25):1671-7. 84. Witz F, Sadoun A, Perrin MC, Berthou C, Brière J, Cahn JY, et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aiguës Myéloblastiques (GOELAM). Blood. 1998;91(8):2722-30. 85. Zittoun R, Suciu S, Mandelli F, de Witte T, Thaler J, Stryckmans P, et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol. 1996;14(7):2150-9. 86. Er O, Coskun HS, Altinbas M, Ozkan M, Eser B, Cetin M, et al. Meropenem +/- granulocyte colony stimulating factor in the treatment of febrile neutropenic patients with cancer: prospective randomized study. J Chemother. 2004;16(3):288-92. 87. Lehrnbecher T, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Creutzig U. Prophylactic human granulocyte colony- stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood. 2007;109(3):936-43. Epub 2006 Sep 28. 88. Little MA, Morland B, Chisholm J, Hole A, Shankar A, Devine T, et al. A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL. Med Pediatr Oncol. 2002;38(2):98-103. 89. Ozkaynak MF, Krailo M, Chen Z, Feusner J. Randomized comparison of antibiotics with and without granulocyte colony- stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2005;45(3):274-80. 90. Patte C, Laplanche A, Bertozzi AI, Baruchel A, Frappaz D, Schmitt C, et al. Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin’s lymphoma: a randomized study of the French Society of Pediatric Oncology. J Clin Oncol. 2002;20(2):441-8. 91. Rodríguez ZN, Tordecilla CJ, Campbell BM, Joannon SP, Rizzardini LC, Soto AV, et al. [Usefulness of G-CSF in pediatric high risk cancer patients with fever and neutropenia]. Rev Chilena Infectol. 2005;22(3):223-7. Epub 2005 Aug 2. Spanish. 92. Thomas X, Boiron JM, Huguet F, Reman O, Sutton L, Turlure P, et al. Efficacy of granulocyte and granulocyte- macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study. Hematol J. 2004;5(5):384-94. 93. Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, Jacquy C, et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer. 2002;10(3):181-8. Epub 2001 Nov 23. 94. Bohlius J, Reiser M, Schwarzer G, Engert A. Impact of granulocyte colony-stimulating factor (CSF) and granulocyte- macrophage CSF in patients with malignant lymphoma: a systematic review. Br J Haematol. 2003;122(3):413-23. 95. Bohlius J, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev. 2004;(1):CD003189. Update of: Cochrane Database Syst Rev. 2002;(4):CD003189. 96. Clark OA, Lyman G, Castro AA, Clark LG, Djulbegovic B. Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev. 2003;(3):CD003039. 97. Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose- intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002;112(5):406-11. 98. Sasse EC, Sasse AD, Brandalise S, Clark OA, Richards S. Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia. Cochrane Database Syst Rev. 2005(3):CD004139. 99. Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J. Meta-analysis: effect of prophylactic hematopoietic colony- stimulating factors on mortality and outcomes of infection. Ann Intern Med. 2007;147(6):400-11. 100. WittmanB, Horan J, LymanGH. Prophylactic colony-stimulating factors in children receivingmyelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. Cancer Treat Rev. 2006;32(4):289-303. Epub 2006 May 5. 101. Roilides E, Farmaki E. Granulocyte colony-stimulating factor and other cytokines in antifungal therapy. Clin Microbiol Infect. 2001;7(Suppl 2):62-7. 102. Blinder VS, Roboz GJ. Hematopoietic growth factors in myelodysplastic syndromes. Curr Hematol Rep. 2003;2(6):453-8. 103. Kojima S, Fukuda M, Miyajima Y, Matsuyama T, Horibe K. Treatment of aplastic anemia in children with recombinant 48